Labcorp has officially announced the completion of its acquisition of Millennium Health, a company specializing in laboratory testing, in a deal with a total value estimated at approximately $375 million. The transaction includes an upfront cash payment of $245 million, in addition to potential future payments linked to achieving specific milestones, valued at up to $130 million.
Enhancing Toxicology Testing Capabilities
This move comes as part of Labcorp's efforts to strengthen its capabilities in the field of toxicology testing and expand its geographic presence to include new regions where it previously lacked sufficient coverage. Millennium Health provides testing based on urine and oral fluid samples to detect prescription drugs, over-the-counter medications, and illicit substances, which aligns with the existing services Labcorp provides to assist physicians in monitoring patients taking controlled substances.
What Does This Acquisition Represent Practically?
Adam Schechter, CEO of Labcorp, explained during the company's earnings call that the drug testing sector is performing strongly, noting that integrating Millennium Health will contribute to increasing competitiveness and facilitating access to medical services in wider areas of the United States. While financial terms were not fully disclosed at the initial announcement of the deal, subsequent financial regulatory filings revealed details regarding the upfront payment and future financial obligations.
Broader Context of Acquisitions
The acquisition of Millennium Health is one of four deals Labcorp concluded during September and October, which also included the purchase of MLM Medical Labs, the laboratory testing operations of BioReference Health, and the prenatal health testing business of Myriad Genetics. Schechter noted that the Protecting Access to Medicare Act (PAMA) is putting pressure on smaller and regional laboratories, creating additional opportunities for expanding partnerships and mergers and acquisitions in the healthcare sector.